María Eugenia Landaeta

María Eugenia Landaeta

Auto-generated profile, based on publicly available information

María Eugenia Landaeta

Department of Infectious Diseases University Hospital of Caracas Caracas Venezuela

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
DFDavid A. Forero-Peña
David A. Forero-Peña
FCFhabián S. Carrión‐Nessi
Fhabián S. Carrión‐Nessi
DMDaniela L. Mendoza‐Millán
Daniela L. Mendoza‐Millán
ÓOÓscar D. Omaña‐Ávila
Óscar D. Omaña‐Ávila
MMMario D. Mejía‐Bernard
Mario D. Mejía‐Bernard
MLMaría E. Landaeta
María E. Landaeta
The coronavirus disease 2019 (COVID‐19) pandemic has particularly affected countries with weakened health services in Latin America, where proper patient management could be a critical step to address the epidemic. In this study, we aimed to characterize and identify which epidemiological, clinical, and paraclinical risk factors defined COVID‐19 infection from the first confirmed cases through the first epidemic wave in Venezuela. A retrospective analysis of consecutive suspected cases of COVID‐19 admitted to a sentinel hospital was carried out, including 576 patient cases subsequently confirmed for severe acute respiratory syndrome coronavirus 2 infection. Of these, 162 (28.1%) patients met the definition criteria for severe/critical disease, and 414 (71.2%) were classified as mild/moderate disease. The mean age was 47 (SD 16) years, the majority of which were men (59.5%), and the most frequent comorbidity was arterial hypertension (23.3%). The most common symptoms included fever (88.7%), headache (65.6%), and dry cough (63.9%). Severe/critical disease affected mostly older males with low schooling (p < 0.001). Similarly, higher levels of glycemia, urea, aminotransferases, total bilirubin, lactate dehydrogenase, and erythrocyte sedimentation rate were observed in severe/critical disease patients compared to those with mild/moderate disease. Overall mortality was 7.6% (44/576), with 41.7% (28/68) dying in hospital. We identified risk factors related to COVID‐19 infection, which could help healthcare providers take appropriate measures and prevent severe clinical outcomes. Our results suggest that the mortality registered by this disease in Venezuela during the first epidemic wave was underestimated. An increase in fatalities is expected to occur in the coming months unless measures that are more effective are implemented to mitigate the epidemic while the vaccination process is ongoing.

19 November 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
DFDavid A. Forero-Peña
David A. Forero-Peña
MHMatthew M. Hernandez
Matthew M. Hernandez
IHIriana Paola Mozo Herrera
Iriana Paola Mozo Herrera
IEIván Bolívar Collado Espinal
Iván Bolívar Collado Espinal
JPJoselyn Páez Paz
Joselyn Páez Paz
APAlberto E. Paniz‐Mondolfi
Alberto E. Paniz‐Mondolfi
Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its relationship the onset and/or exacerbation of mental disease. However, coronavirus disease 2019 (COVID‐19) treatments, themselves, must be considered as potential catalysts for new‐onset neuropsychiatric symptoms in COVID‐19 patients. To date, immediate and long‐term neuropsychiatric complications following SARS‐CoV‐2 infection are currently unknown. Here we report on five patients with SARS‐CoV‐2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine and dexamethasone in these neuropsychiatric presentations.

7 August 2022 in HIV Medicine
Verified
Journal Article
Closed access
YGYoel D. García
Yoel D. García
FUFrancisco A. Ureña
Francisco A. Ureña
FCFhabián S. Carrión‐Nessi
Fhabián S. Carrión‐Nessi
SDSol Y. Díaz
Sol Y. Díaz
AÁAtahualpa A. Ávila
Atahualpa A. Ávila
DFDavid A. Forero-Peña
David A. Forero-Peña

10 October 2020 in Gaceta Médica de Caracas
Verified
Journal Article
Closed access
DMDaniela Mendoza Millán
Daniela Mendoza Millán
ÓÁÓscar Omaña Ávila
Óscar Omaña Ávila
DRDaniela Restuccia
Daniela Restuccia
DFDavid Flora-Noda
David Flora-Noda
AMAndrea Maricuto
Andrea Maricuto
MLMaría Eugenia Landaeta
María Eugenia Landaeta
La enfermedad por Coronavirus 2019 (COVID-19) continúa siendo un serio problema de salud pública en todo el mundo, sin embargo, hasta la fecha, existe información limitada sobre el comportamiento de esta pandemia en América Latina y en particular en Venezuela. En este trabajo se describe la experiencia del Hospital Universitario de Caracas (HUC) durante la pandemia de la COVID-19. Posterior al reporte del primer caso de infección en el país el 13 de marzo del 2020, el HUC instauró una carpa para la atención y diagnóstico de pacientes sospechosos de la COVID-19; para el 31 de agosto un total de 6 532 pacientes habían sido atendidos en el HUC, y se habían realizado 1 589 pruebas de PCR-RT, confirmándose la infección en 732 (46 %) pacientes, con una edad media de 47 años (12-82), siendo la mayoría hombres (57,7 %). El subregistro de casos ha sido un factor común en el desarrollo de la pandemia COVID-19 en todos los países, Venezuela no es la excepción. Los estudios prospectivos nos advierten de una mayor frecuencia de eventos catastróficos en las próximas décadas, por lo que se hace necesario preparar a las sociedades para anticipar y gestionar los riesgos, esta pandemia puede ser la primera de muchas por venir.

1 January 2020 in Pesquisa Brasileira em Odontopediatria e Clínica Integrada
Verified
Journal Article
Open access
PDF file
JPJacinto Pineda
Jacinto Pineda
RMRommie Merino-Alado
Rommie Merino-Alado
SMSofia Mata-Essayag
Sofia Mata-Essayag
MLMaria Eugenia Landaeta
Maria Eugenia Landaeta
LGLiseloth Garrido
Liseloth Garrido
MRMaria del Mar Rosas
Maria del Mar Rosas
Objective: To determine the prevalence of nasal septum perforation associated to Histoplasma sp. Material and Methods: A retrospective descriptive study was conducted with patients who developed nasal septum perforation associated to histoplasmosis. The diagnosis was made based on clinical manifestations and confirmed with mycological direct examination with Giemsa stain, culture, serologic tests (immunodiffusion method), and histopathology with hematoxylin-eosin, Grocott methenamine (GMS) and Periodic Acid-Schiff stain (PAS). Results: Out of 1654 medical records reviewed with diagnosis of histoplasmosis in the study period, we found 22 cases with nasal septum perforation. Autoimmune disease was present in 6 patients; all six were on immunosuppressive treatment. Two patients had HIV/AIDS, one of them had also paracoccidiodomycoses and the remaining had no apparent underlying disease or conditions. Conclusion: Physicians of endemic areas such as Venezuela, must consider this entity in the differential diagnosis with other diseases.